Early Alectinib Resistance From MET Amplification in ALK-Rearranged NSCLC: Response to Crizotinib with Re-Response to Alectinib and Crizotinib

Jingran Ji; Anupam Mitra; D. Ross Camidge; Jonathan W. Riess

doi:10.1016/j.cllc.2021.04.008

Early Alectinib Resistance From MET Amplification in ALK-Rearranged NSCLC: Response to Crizotinib with Re-Response to Alectinib and Crizotinib

Jingran Ji, Anupam Mitra, D. Ross Camidge, Jonathan W. Riess

Hematology and Oncology

Research output: Contribution to journal › Article › peer-review

Abstract

• Crizotinib is active as second-line therapy against MET-mediated resistance to alectinib in anaplastic lymphoma kinase (ALK)-rearranged non–small-cell lung cancer and can be used in combination. • Repeat molecular analyses including assessment of MET amplification can help guide therapy in ALK-positive non–small-cell lung cancer.

Original language	English (US)
Journal	Clinical lung cancer
DOIs	https://doi.org/10.1016/j.cllc.2021.04.008
State	Accepted/In press - 2021

Keywords

ALK inhibitor resistance
ALK mutation
MET amplification
MET inhibition
Non–small-cell lung cancer

ASJC Scopus subject areas

Oncology
Pulmonary and Respiratory Medicine
Cancer Research

Access to Document

10.1016/j.cllc.2021.04.008

Cite this

@article{4235da8a49154220bcf69d230b2c7d92,

title = "Early Alectinib Resistance From MET Amplification in ALK-Rearranged NSCLC: Response to Crizotinib with Re-Response to Alectinib and Crizotinib",

abstract = "• Crizotinib is active as second-line therapy against MET-mediated resistance to alectinib in anaplastic lymphoma kinase (ALK)-rearranged non–small-cell lung cancer and can be used in combination. • Repeat molecular analyses including assessment of MET amplification can help guide therapy in ALK-positive non–small-cell lung cancer.",

keywords = "ALK inhibitor resistance, ALK mutation, MET amplification, MET inhibition, Non–small-cell lung cancer",

author = "Jingran Ji and Anupam Mitra and Camidge, {D. Ross} and Riess, {Jonathan W.}",

note = "Publisher Copyright: {\textcopyright} 2021",

year = "2021",

doi = "10.1016/j.cllc.2021.04.008",

language = "English (US)",

journal = "Clinical Lung Cancer",

issn = "1525-7304",

publisher = "Elsevier",

}

TY - JOUR

T1 - Early Alectinib Resistance From MET Amplification in ALK-Rearranged NSCLC

T2 - Response to Crizotinib with Re-Response to Alectinib and Crizotinib

AU - Ji, Jingran

AU - Mitra, Anupam

AU - Camidge, D. Ross

AU - Riess, Jonathan W.

PY - 2021

Y1 - 2021

N2 - • Crizotinib is active as second-line therapy against MET-mediated resistance to alectinib in anaplastic lymphoma kinase (ALK)-rearranged non–small-cell lung cancer and can be used in combination. • Repeat molecular analyses including assessment of MET amplification can help guide therapy in ALK-positive non–small-cell lung cancer.

AB - • Crizotinib is active as second-line therapy against MET-mediated resistance to alectinib in anaplastic lymphoma kinase (ALK)-rearranged non–small-cell lung cancer and can be used in combination. • Repeat molecular analyses including assessment of MET amplification can help guide therapy in ALK-positive non–small-cell lung cancer.

KW - ALK inhibitor resistance

KW - ALK mutation

KW - MET amplification

KW - MET inhibition

KW - Non–small-cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=85107045305&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85107045305&partnerID=8YFLogxK

U2 - 10.1016/j.cllc.2021.04.008

DO - 10.1016/j.cllc.2021.04.008

M3 - Article

AN - SCOPUS:85107045305

JO - Clinical Lung Cancer

JF - Clinical Lung Cancer

SN - 1525-7304

ER -

Early Alectinib Resistance From MET Amplification in ALK-Rearranged NSCLC: Response to Crizotinib with Re-Response to Alectinib and Crizotinib

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this